Table 1 Patient demographics and clinical characteristics

Characteristic

No. (%)

No. (%)

 Gender

  Male

72 (51.1%)

50 (56.2%)

  Female

69 (48.9%)

39 (43.8%)

 Age (years)

  ≤ 42

19 (13.5%)

11 (12.4%)

  > 42

122 (86.5%)

78 (87.6%)

 Family history

  Yes

36 (25.5%)

18 (20.2%)

  No

105 (74.5%)

71 (79.8%)

 Smoking behaviour

  Yes

84 (59.6%)

50 (56.2%)

  No

57 (40.4%)

39 (43.8%)

 BMI

  ≥ 25

30 (21.3%)

14 (15.7%)

  18.5 ≤ BMI < 25

103 (73.0%)

65 (73.0%)

  < 18.5

8 (5.7%)

10 (11.3%)

 TNM stage^a

  I

31 (22.0%)

23 (25.8%)

  II

17 (12.1%)

6 (6.7%)

  III

53 (37.6%)

34 (38.2%)

  IV

40 (28.3%)

26 (29.3%)

 Size (cm)^b

  ≤ 6.3

122 (86.5%)

70 (78.7%)

  > 6.3

19 (13.5%)

19 (21.3%)

 Treatment

  Surgery

37 (26.2%)

21 (23.6%)

  Radiotherapy/chemotherapy

47 (33.3%)

31 (34.8%)

  Surgery and radiotherapy/chemotherapy

49 (34.8%)

25 (28.1%)

  Other

8 (5.7%)

12 (13.5%)

 ALT (U/L)

  ≤ 12.5

15 (10.6%)

11 (12.4%)

  > 12.5

126 (89.4%)

78 (87.6%)

 AST (U/L)

  ≤ 22.0

73 (51.8%)

45 (50.1%)

  > 22.0

68 (48.2%)

44 (49.9%)

 SLR

  ≤ 1.24

102 (72.3%)

61 (68.5%)

  > 1.24

39 (27.7%)

28 (31.5%)

 APOAI (g/L)

  ≤ 1.17

56 (39.7%)

39 (43.8%)

  > 1.17

85 (60.3%)

50 (56.2%)

 APOB (g/L)

  ≤ 0.99

92 (65.2%)

50 (56.2%)

  > 0.99

49 (34.8%)

39 (43.8%)

 ALP (U/L)

  ≤ 82.9

96 (68.1%)

51 (57.3%)

  > 82.9

45 (31.9%)

38 (42.7%)

 ALB (g/L)

  ≤ 40.1

108 (76.6%)

62 (69.7%)

  > 40.1

33 (23.4%)

27 (30.3%)

 GGT (U/L)

  ≤ 44.2

117 (83.0%)

72 (80.9%)

  > 44.2

24 (17.0%)

17 (19.1%)

 LDH (U/L)

  ≤ 245.6

125 (88.7%)

77 (86.5%)

  > 245.6

16 (11.2%)

12 (13.5%)

 TBIL (μmol/L)

  ≤ 13.6

113 (80.1%)

61 (68.5%)

  > 13.6

28 (19.9%)

28 (31.5%)

 DBIL (μmol/L)

  ≤ 3.3

67 (47.5%)

38 (42.7%)

  > 3.3

74 (52.5%)

51 (57.2%)